Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.

Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.

Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-onset type 1 diabetes.The randomised placebo-controlled Diabetes...

Full description

Bibliographic Details
Main Authors: Stephan Martin, Christian Herder, Nanette C Schloot, Wolfgang Koenig, Tim Heise, Lutz Heinemann, Hubert Kolb, DIATOR Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-03-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3055882?pdf=render

Internet

http://europepmc.org/articles/PMC3055882?pdf=render

Similar Items